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The HIV-1 gp120 V3 loop is a potent inducer of neutralizing antibodies for T cell line adapted-HIV-1, but less so for primary isolates. We
hypothesized that peptides representative of the diversity of natural HIV-1 V3 loop variants might capture elements of conserved higher order
structures and so stimulate broadly reactive neutralizing antibodies. We designed a panel of 29 subtype B V3 sequences postulated to reflect the
range of V3 diversity. These peptides were used to immunize guinea pigs. The most effective peptide (62.19) clustered around the subtype B
consensus sequence and induced antibodies that reproducibly neutralized 31% of the subtype B HIV-1 primary isolates evaluated, but exhibited
limited cross-neutralization of non-subtype B HIV-1 strains. Taken together, these data demonstrated that the limited neutralization profile of
antibodies induced by optimal subtype B V3 motifs likely represents the maximum breadth of neutralization of subtype B HIV-1 primary isolates
attainable by anti-V3 peptide antibodies.
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Design of HIV-1 immunogens capable of inducing high-titer
antibodies that neutralize a broad spectrum of HIV-1 primary
isolates is a major priority for HIV-1 vaccine development.
When the gp120 third variable region (V3) loop was identified
as a potent neutralizing determinant for T cell line adapted
(TCLA) strains of HIV-1, it was thought that gp120 or a V3
subunit would be an important component of an HIV-1 vaccine
(Javaherian et al., 1989; LaRosa et al., 1990; Palker et al.,
1988, 1989; Rusche et al., 1988). However, observations that
anti-V3 antibodies poorly neutralize HIV-1 primary isolates in0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.08.042
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E-mail address: hayne002@mc.duke.edu (B.F. Haynes).PBMC (Hanson, 1994; Matthews, 1994) dampened enthusiasm
for the gp120 V3 loop as a vaccine target.
Recent studies, however, suggested that certain antibodies
reactive with the V3 loop can indeed neutralize HIV-1 primary
isolates, and have rekindled interest in developing V3
immunogens as targets for antibodies that can broadly
neutralize HIV primary isolates. Hioe et al. (1997) have shown
that polyclonal and human monoclonal antibodies (mabs)
against V3 can neutralize select HIV-1 primary isolates. Liao
et al. (2000) used C4–V3 peptides with the V3 loops of
gp12089.6 and gp12089.6P to induce antibodies in guinea pigs
and monkeys that neutralized SHIV89.6 in vitro. Krachmarov et
al. (2001) affinity purified anti-V3 antibodies from HIV-1+
human serum and demonstrated effective anti-V3 neutraliza-
tion of HIV-1 primary isolates. Finally, Letvin et al. (2001)
showed that C4–V389.6P-immunized rhesus monkeys were
protected from SHIV89.6P-induced CD4+ decline. Taken06) 44 – 55
www.e
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anti-V3 antibodies can prevent primary isolate SHIV-induced
disease, and could be a relevant target for neutralization of
primary HIV-1 isolates.
The V3 loop has important functions in HIV-1 Env-
mediated fusion. Amino acid charge in the V3 loop can
determine HIV-1 tropism and co-receptor usage (Chesebro et
al., 1988; de Jong et al., 1992; Fouchier et al., 1992; Milich et
al., 1993; Shioda et al., 1992). Moreover, the V3 region is
located within gp120 adjacent to the co-receptor binding site,
and participates in co-receptor interactions with gp120 (Hu et
al., 2000; Ping et al., 1999; Shioda et al., 1992; Trkola et al.,
1996; Wang et al., 1999; Wu et al., 1996). Thus, in spite of the
remarkable variability within V3, it is likely that conserved
higher order structures of the V3 region exist that are
critical for co-receptor binding and HIV-1 infectivity
(Catasti et al., 1996). In this regard, Sharon et al. have
studied the structure of V3 peptides bound to a neutralizing
human mab, 447-52D, and found structural similarities
between the V3 loop and the chemokines that are natural
ligands for HIV-1 co-receptors (Sharon et al., 2003)
although it was not shown that the chemokine loop is
involved in chemokine receptor binding.
In an effort to design V3 immunogens that would induce
neutralizing antibodies of maximum breadth for HIV-1
primary isolates, we have clustered subtype B V3 sequences
available in the HIV database into like-groups based on a
sequence diversity scoring system (Korber et al., 1994) using
an amino acid substitution matrix that incorporated structure
(Henikoff and Henikoff, 1993). We have tested selected V3
peptides for their ability to bind human neutralizing anti-V3
mabs, and for their ability to induce neutralizing antibodies
against HIV-1 primary isolates in guinea pigs. We found
our selection process to clearly define HIV-1 gp120 V3
motifs with better capacities for induction of neutralizing
antibodies than others. However, the selected V3 motifs
induced neutralizing antibodies against a minor subset of
HIV-1 primary isolates, thus defining the limits of V3
peptide subunits as components of an experimental HIV-1
vaccine.
Results
Design of HIV-1 subtype B V3 peptides for immunogenicity
studies
In the 2001 Los Alamos HIV Sequence Database
(www.LANL.gov), there were 6870 subtype B V3 sequences
from the United States of which there were 1514 unique forms.
From these 1514 sequences, we chose 30 peptides as described
in Methods, of which 29 could be successfully synthesized and
purified. The initial selection of representative sequences was
based on primary amino acid (aa) alignment, using maximum
linkage clustering (Korber et al., 1994). The related clusters
were then scored for similarity based on the presence of those
aa that are predicted not to markedly affect higher order
structures (e.g. LysY Arg) versus those aa changes that wouldmarkedly affect structure (e.g. Phe Y Arg) (Henikoff and
Henikoff, 1993). Finally, a representative of each of 30 clusters
was selected by inspection of viral sequences using two
criteria. First, within the context of each cluster, we attempted
to select a sequence that was repeated many times in the
complete data set of 6870 sequences, as we reasoned that
frequent repetition of a sequence was indicative of a loop that
retained a favorable conformation for the virus, and that a
loop that was naturally repeated many times was more likely
to elicit antibodies that could cross-react with multiple
isolates. Second, we selected a sequence that was central to
the cluster, not an outlier, to minimize the distance to all other
sequences in an attempt to provide the best coverage of the
cluster (Fig. 1).
The peptides chosen for synthesis are shown in Table 1.
Each synthesized peptide had the C4 region synthesized N-
terminal to the V3 region for maximum immunogenicity
(Haynes et al., 1995; Palker et al., 1989). The consensus
sequence (a concatenation of the most common amino acid in
every position in the alignment) based on the unique
sequence alignment of 1514 peptides of the subtype B V3
region is reflected in sequence 1.481. Peptide 1.481 was
present 481 times in the complete set of 6870 sequences. As
the most commonly observed peptide, it was ranked first and
assigned ‘‘1’’ at the beginning of its identifier. When a
sequence/putative motif was present only once, as was the
case with sequence 1448.1, it was chosen because it was
deemed most representative of a cluster of related peptides,
and meeting the second criteria for representative peptide
selection in a cluster where no sequence was found repeated
in the full set of peptides.
Immunization of guinea pigs with C4–V3 subtype B peptides
A single guinea pig was immunized with each subtype B
C4–V3 peptide to generate 29 pre- and post-bleed paired sera
that were screened for peptide immunogenicity using a single
round pseudotype virion neutralization assay (Tables 1 and 2).
A spectrum of breadth of 50% neutralizing antibody
responses of 20 HIV-1 isolates (19 B subtype, one AG
subtype) was observed; 10/29 C4–V3 peptide sera were
unable to neutralize any of the isolates tested, while one
peptide sera (62.19) was able to neutralize 8 isolates (Tables 1
and 2). It is interesting to note that peptide 62.19 does not
completely correspond to the consensus; the sequence near
the tip of the loop is identical, but 62.19 has two substitutions
near the C-terminal end.
Because human anti-V3 Mabs 447-52D and 39F neutralize
HIV-1 primary isolates (Gorny et al., 2002; Gorny et al., 2004)
(James Robinson, personal communication), we tested the
ability of these two human Mabs to bind the subtype B C4–V3
peptides in ELISA assays. Peptides that induced antibodies that
neutralized 3 HIV isolates had significantly higher OD at 405
nm binding to Mabs 39F (P < 0.0002) and 447-52D (P <
0.0001), than did the 10 C4–V3 peptides that were unable to
neutralize any HIV-1 primary isolates (Table 1) (Fig. 2). Thus,
from these data of peptide binding to Mab 447-52D, we
Fig. 1. Schematic representation of the process and method of V3 region selection. Figure shows a phenogram of B subtype V3 loops sequences. 6870 B subtype V3
sequences from the US were extracted from the HIV database, and these were reduced to 1514 unique forms. Each unique form was assigned a number, and the
number of times it was in the full set of sequences tallied. For example, peptide 11.85 was the eleventh peptide in the set of 1514 peptides, when they were ordered
from most to least frequent, and it was observed 85 times in the full set of 6870 sequences. An amino acid-based similarity score was obtained for each peptide pair,
and the sequences were then clustered based on these pairwise scores as described in Methods and in Korber et al. (1994). Pairwise scores approaching 145 were
obtained for nearly identical sequences. The clustering pattern, which we call a phenogram (19) as the amino acid-based similarity scores are intended to reflect
structural and functional protein relationships and not evolutionary relationships, is shown on the left hand side of the figure. The alignment of sequences from two
example clusters are shown on the right, one cluster is marked in the phenogram in red, the other in red, the other in green. The alignments are shown relative to the
consensus, with dashes indicating identical amino acids. Our goal was to sample a diverse range of common V3 sequences, selecting a manageable number of
representatives for experimental testing. The clustering method grouped similar sequences, and from within each group, we then selected by eye representative
sequences that met the criteria of being duplicated many times within the full data set, and being reasonably central to the cluster. The sequences selected to represent
the two examples clusters are marked with asterisks, and these were included among the test set summarized in Table 1.
B.F. Haynes et al. / Virology 345 (2006) 44–5546inferred that a number of V3 peptides in Table 1 could assume
the form of the putative higher order V3 structure similar to the
reported NMR structure of HIVMN V3 peptide bound to Mab
447-52D (Vu et al., 1999). A lack of binding to the human
monoclonals could be the result of specific amino acid
substitutions in the epitope; for example, the core epitope for
the 447-52D Mab is GPxR (Conley et al., 1994), and only 17
of the 29 peptides we selected matched this epitope. The otherswere commonly observed natural variants; three variants also
bound to 447-52D, including GPGG, GPGK, and APGR, but
others did not, for example GLGR, GMGR, and GPGS.
Blue native gel analysis
Next, we used blue native gel analysis to evaluate reactivity
of the antisera induced by the five most immunogenic C4–V3
Table 1
Peptide sequence, number of isolates neutralized by sera elicited by the peptide vaccine, and the ability of human anti-V3 mabs to react with the peptide
The peptide name in the first column lists the number of peptide in the alignment, organized by frequency of identical peptides found among the 6870 B subtype
sequences available. For example, peptide 1.481 was the most common peptide in the set, so ranked first, and was found 481 times. When a peptide was only
observed once, like 1448.1, it was still deemed most representative of a cluster of related peptides.
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neutralizing antibody responses in Table 1) with HIV-1
proteins. Sera from animals immunized with the C4–V3
peptides 1.481, 11.85, 34.29, 36.29, and 62.19, as well as
sera from a poorly immunogenic peptide, 74.17, were tested
in Western blot of blue native polyacrylamide gel analysis
against three subtype B HIV-1 Env proteins (89.6, Bal, and
JRFL), a subtype C rgp140 (97ZA012), and a group M
consensus rgp140 (CON6) (Fig. 3). These recombinant HIV-
1 Env proteins are mostly monomers for gp120s (89.6 and
BaL) and oligomers for gp140s (JRFL, 97ZA012 and
CON6) in blue native polyacrylmide gel analysis (Fig.
3A). We found that anti-C4–V3 11.85, 34.29, 1.281, and
62.19 peptide sera reacted with all 3 subtype B HIV-1 Env
proteins and the group M consensus CON6 Env rgp140 but
did not react with subtype C rgp140 (Fig. 3B). Anti-C4–V3
36.29 serum reacted weakly only with JRFL and CON6
rgp140, while anti-C4–V3 74.17 as well as normal guinea
pig sera did not react with any of these 5 HIV-1 Env
proteins (Fig. 3B).Immunization of selected best subtype B V3 peptides into
multiple guinea pigs
Because our initial screen of peptide immunogenicity used
only one guinea pig immunized with each peptide, to confirm
our peptide selection, we immunized 4 guinea pigs per group in
CFA/IFAwith the 1.481, 11.85, 34.29, 62.19, and 36.29 C4–V3
peptides, as well as with the less optimal C4–V3 peptide, 74.17.
We also immunized an additional four guinea pigs with the
above peptides in a synthetic monophosphoryl lipid A adjuvant,
RC529, that was mixed with 10 Ag of mCT S.Q. in squalene, to
ensure maintenance of any higher order peptide structures.
Table 3 summarizes the neutralization results in the luciferase
reporter gene-based multiple-round HIV-1 inhibition assay of
sera from animals immunized with C4–V3 peptides in CFA/
IFA; similar neutralization results were obtained in animals
immunizedwith C4–V3 peptides in RC529 +mCT (not shown).
We found that C4–V3 peptides 1.481, 11.85, 34.29, and
62.19 all induced antibodies that were able to neutralize 3 to 5 of
the subtype B HIV-1 primary isolates tested (positive neutral-
Table 2
Envelope gp120 V3 sequences of HIV isolates used to screen serum raised against subtype B V3 peptide immunogens
Of note, the only perfect match over the 23 amino acid region used to design the peptides was between JRFL, and possibly BAL, and the peptide 1.481. The ‘‘X’’
signifies a mixture of amino acids in a given position.
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neutralized (BaL, BX08, SF162, SS1196, and QH0692), the
first 4 isolates are traditionally more easily neutralized with
sCD4 and sera from HIV+ individuals, while HIV-1 isolates
6101, QH0692, and BG1168 are less easily neutralized. As
expected, the C4–V3 peptide 74.17 generated no neutralization
activity (0/7 isolates neutralized). Thus, these data validated our
screen of the initial single C4–V3 sera (Table 1), and showed
that the best C4–V3 immunogen, 62.19, induced antibodies
that neutralized 5 of 7 of the subtype B isolates tested. One can
see from the V3 sequences in Table 1 that the selected peptidesFig. 2. Comparison of the ability of peptides that induced neutralizing antibodies
to 3 HIV-1 isolates versus peptides that were unable to induce neutralizing
antibodies to bind 447-52D and 39F mabs. Peptides that induced antibodies that
neutralized 3 HIV-1 isolates bound significantly better to both mabs (P <
0.0002 to 39F and P < 0.0001 to 447-52D) than peptides that did not induce
neutralizing antibodies.are similar to the V3 subtype B consensus amino acid sequence,
which corresponds to the sequence of peptide 1.481. The
specific changes relative to 1.481 tend to be defining amino
acids for each of the 30 clusters.
Breadth and extent of neutralization activity of anti-C4–V3
peptide sera
To rule out possible artifacts from the use of whole serum in
neutralization assays, we tested the ability of purified IgG from
two sets of peptide sera (11.85, 62.19) to neutralize nine HIV-1
isolates in the single round pseudotype virion neutralization
assay (Table 4). These data showed neutralization activity of
anti-V3 IgG against the neutralization-sensitive HIV-1 strains
in the panel (SS1196, BaL, BX08, NL43, and SF162) but not
against several other HIV-1 subtype B isolates (5768, 6101,
DUAL/B, DUAL/E, JRCSF, TORNO). While the breath of
neutralization was the same as in Table 3 using whole serum,
the purified IgG preparations often had lower titers likely due
to dilution effect during IgG purification process and assay
differences. Some of the isolates that were not readily
neutralized, for example TORNO and JRCSF (both have the
sequence SIHIGPGRAFY), share sequences at the tip of the
V3 loop with the immunizing peptide 62.19, suggesting that
there are conformational or V3 exposure issues limiting
neutralization sensitivity in these cases.
Next, we tested antisera raised against C4–V3 peptides
11.85 and 62.19 against SHIVSF162-P3 using luciferase-based
multiple-round HIV-1 inhibition assay, SHIV89.6 and
SHIV89.6P, using the MT-2 assay. With the exception of
sporadic low titers against SHIVSF162-P3, there was no
significant neutralization of SHIVs by the anti-C4–V3 subtype
B.F. Haynes et al. / Virology 345 (2006) 44–55 49B peptide antisera (data not shown). Thus, of the 16 subtype B
HIV-1 isolates tested in Tables 3 and 4, peptide 11.85
neutralized 4/16 (25%) and 62.19 neutralized 5/16 (31%).Fig. 3. Blue native gel and Western blot analysis of anti-subtype B V3 antisera a
indicated on the top of each gel were analyzed on blue native 3–8% polyacrylam
Millipore) for Western blot analysis. Shown in panel A is the Coomassie blue stain
indicate these HIV-1 proteins that exist as monomers, dimmers, trimers, and in the
panel B is the reactivity of six anti-V3 guinea pig sera and normal guinea pig contro
subtype B HIV-1 Env proteins (89.6 rgp120, BaL rgp120, and JRFL rgp140), 1 subty
antibodies against peptide 74.17 and normal guinea pig sera did not react, the bestWe also tested the best anti-V3 antisera against strains of
HIV-1 subtypes A, C, D, and E using the luciferase-based
multiple-round HIV-1 inhibition assay. No consistent neu-gainst recombinant HIV-1 Env proteins. Recombinant HIV-1 Env proteins as
ide gel and transferred to polyvinylidene difluoride membranes (Immobilon,
of the non-denaturing native gel analysis of HIV-1 Env proteins. Arrow heads
case of the group M consensus Env rgp140, CON6, tetramer forms. Shown in
l sera in Western blot analysis as indicated in the bottom of each panel, with 3
pe C rgp140 (97ZA012), and group M consensus Env rgp140, CON6. Whereas
peptide antisera reacted with the subtype B and consensus HIV-1 Env proteins.
Table 3
Neutralization titers of pre- and post-immune guinea pig sera induced with C4–V3 peptides formulated in CFA/IFA against subtype B primary HIV-1 strains
Immunogen (250 Ag/dose) GP # Neutralizing antibody titers against HIV primary isolates
BAL BG1168 BX08 6101 SF162 SS1196 QH0692
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
C4–V3-1.481 597 28 106 <20 20 <20 167 63 85 <20 63 24 90 55 127
598 <20 167 <20 <20 <20 230 51 86 <20 210 <20 99 37 127
599 <20 84 27 29 <20 195 73 98 <20 244 20 92 71 133
600 21 120 28 35 <20 119 73 66 <20 178 27 168 42 82
C4–V3-11.85 601 38 174 <20 28 <20 785 42 94 <20 10,424 <20 187 <20 177
602 51 72 <20 70 <20 181 94 108 <20 139 <20 58 <20 38
603 38 42 <20 25 37 >540 46 82 <20 133 <20 39 <20 42
604 29 45 14 23 32 198 76 107 <20 338 <20 14 <20 34
C4–V3-34.29 605 <20 81 <20 26 <20 254 30 50 <20 413 54 212 48 196
606 <20 59 <20 26 <20 156 51 65 <20 5498 37 338 59 203
607 <20 34 <20 34 <20 71 52 87 <20 2761 24 99 20 46
608 <20 55 <20 26 <20 59 74 78 <20 240 26 76 <20 163
C4–V3-62.19 609 <20 168 27 77 <20 172 70 157 <20 119 50 315 <20 286
610 <20 102 <20 20 <20 220 27 75 <20 21 <20 126 <20 103
611 <20 117 <20 54 <20 86 41 70 <20 124 30 189 <20 125
612 <20 124 <20 30 <20 49 49 72 <20 390 21 223 <20 338
C4–V3-36.29 617 <20 233 <20 26 <20 196 64 72 <20 158 23 268 40 100
618 <20 183 <20 43 <20 108 67 82 <20 3845 23 153 36 93
619 <20 121 <20 <20 <20 95 71 45 <20 48 <20 75 32 69
620 <20 166 <20 44 <20 214 88 108 <20 65 <20 161 40 94
C4–V3-74.17 613 44 65 <20 27 76 116 63 58 <20 <20 <20 <20 <20 33
614 52 62 <20 26 217 104 119 135 <20 35 <20 <20 42 61
616 43 88 <20 <21 128 141 105 152 <20 21 <20 <20 <20 32
Data in this table were all from post-immune 4 GP sera and corresponding pre-bleeds. The sera were diluted starting at 1:20, the titers were determined when 50% of
inhibition compared to virus control was achieved. Bold = those positive values where post/pre-ratio is greater than 3 and post-value >30.
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except for the reactivity of anti-11.85 sera against the subtype
C isolate, TV-1 (data not shown).
Analysis of suboptimal anti-C4–V3 antisera
An important goal of this study was to determine if a
polyvalent immunogen could be designed that would broadly
neutralize HIV-1 subtype isolates. However, when we analyzedTable 4
Ability of purified IgG fractions of selected C4–V3 immune sera to neutralize HIV
Animal no. Immunogen Antibody titers in neutralization assay aga
SS1196 5768 6101 BAL BX08 D
601 11.85 270 <10 <10 270 270 <
602 11.85 10 <10 <10 30 90
603 11.85 <10 <10 <10 30 30 <
604 11.85 <10 <10 <10 30 30 <
609 62.19 90 <10 <10 90 270 <
610 62.19 90 <10 <10 270 270 <
611 62.19 30 <10 <10 90 90 <
612 62.19 90 <10 <10 90 90 <
NLGP#1 Negative control <10 <10 <10 <10 <10 <
NLGP#2 Negative control <10 <10 <10 <10 <10 <
NLGP#3 Negative control <10 <10 <10 <10 <10 <
HIV + plasma Positive control 270 90 10 270 270
IgG1b12 25 Ag/ml Positive control 90 270 <10 270 270 <
Pre-incubation HITS in neutralization assay (ViroLogic). All guinea pig antibody
equivalent to the dilutions of unpurified immune serum samples. Bold = those po
a Assay is 18 h.those isolates that were neutralized by the suboptimal antipep-
tide sera (i.e. peptides 144.8 through 34.29 in Table 1), we
found that all neutralization sensitive strains were also
neutralized by anti-62.19 and as well as by the other selected
antisera (data not shown), i.e. there were no strains neutralized
by suboptimal peptide sera that were not also neutralized by
anti-62.19 sera. Thus, no group of peptides could be predicted
to be more effective as an immunogen than the 62.19 peptide
alone. Moreover, when the 62.19 peptide was combined with 4-1 isolates in the single round pseudotype virion neutralization assaya
inst HIV-1 isolates Amphotropic MLVl
UAL B DUAL E JRCSF NL43 SF12 TORO
negative control
10 <10 <10 270 270 <10 <10
<10 <10 270 270 <10 <10
10 <10 <10 90 270 <10 <10
10 <10 <10 <10 270 <10 <10
10 <10 <10 <10 270 <10 <10
10 <10 <10 <10 90 <10 <10
10 <10 <10 <10 270 <10 <10
10 <10 <10 <10 270 <10 <10
10 <10 <10 <10 <10 <10 <10
10 <10 <10 <10 <10 <10 <10
10 <10 <10 <10 <10 <10 <10
90 <10 270 270 270 90 <10
10 <10 270 270 270 <10 <10
samples were purified IgG, and titers of purified IgG were calculated to be
sitive values where post-value 30.
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polyvalent antisera were generated in 3 guinea pigs, no
improvement in neutralization breadth was observed (data not
shown).
We noted that the peptide immunogens that were unable to
induce neutralizing anti-subtype B antibody responses fre-
quently contained non-GPGR V3 crown sequences (e.g.
GLGR, GPGG, GMGR). Importantly, the V3 crown
sequences of the 19 HIV-1 isolates that we analyzed in
neutralization assays were predominately GPGR (Table 2).
Therefore, to determine if sera raised against non-GPGR
motif peptides would neutralize non-GPGR HIV-1 isolates,
which are relatively common in vivo, we tested five non-
GPGR peptide antisera (196.2, 170.6, 23.38, 51.23, and
57.20) against two subtype B isolates with GPGG V3 crown
sequences, two subtype B isolates with GLGR V3 crown
sequences, a GPGQ subtype C isolate, and JRCSF and NL43
GPGR subtype B isolates in the single round pseudotype
virion assay. We found that serum 447 that was raised against
a GLGR V3 peptide (396.2) weakly neutralized the GPGG#1
isolate but did not neutralize either GLGR isolates (50%
neutralization titer = 30). In addition, serum 451 raised
against a GLGK V3 peptide (Korber et al., 1994) weakly
neutralized the GLGR#2 subtype B isolate. However, the
remainder of the non-GPGR sera tested did not neutralize
non-GPGR HIV-1 isolates, suggesting that these peptide
motifs do not have particular utility in inducing neutralizing
antibodies against non-GPGR HIV-1 isolates. However, we
cannot rule out that these antisera raised against non-GPGR
V3’s would have neutralized other non-GPGR HIV-1 strains
if more isolates had been tested.
Discussion
In this study, we have chosen peptides based on predicted
higher order structures of subtype B gp120 V3 region, and
performed immunizations with selected peptides to deter-
mine if V3 immunogens could be identified that induced
broadly reactive neutralizing antibodies to HIV-1 primary
isolates. The premise of this study was that in spite of the
variability of gp120 V3 sequences, conserved higher order
motifs of V3 likely exist, and that antibodies against
combinations of these motifs might neutralize HIV primary
isolates with greater breadth than previously described anti-
V3 antibodies that are predominantly strain-specific. Our
study showed that we could identify subtype B V3 motifs
that have the ability to induce neutralizing antibodies against
subtype B primary isolates, but the resulting neutralizing
antibodies were restricted to a limited subset of subtype B
primary isolates.
The selection of five subtype B V3 motifs that induced
more breadth of neutralizing antibodies than other V3 motifs
in our initial screen was corroborated by subsequent
immunization studies in multiple animals. However, we
expected to identify several motifs that were capable of
inducing neutralizing antibodies against distinct subsets of
HIV-1 primary isolates. Rather, we identified a series of V3motifs with sequences that clustered around the subtype B
consensus sequence, and all selected V3 peptides induced
similar neutralizing specificities, i.e. each selected peptide-
induced antibodies that neutralized the same subset of HIV-1
isolates. Moreover, the neutralizing activity of antibodies
induced by V3 peptides were limited to a group of HIV-1
isolates that are relatively easy to neutralize.
The subtype B isolates neutralized by anti-C4–V3
subtype B antisera included the four most easy to neutralize
HIV-1 isolates in the panel (BaL, SS1196, BX08, SF162).
QH0692 was neutralized but not at titers as high as the
HIV+ human sera control. Most importantly, when purified
IgG from these sera was tested against an expanded panel
of subtype B isolates in the single round pseudotype virion
assay, no additional HIV-1 isolates were neutralized. Thus,
it appears with this strategy of V3 immunogen selection,
that the neutralization results obtained with C4–V3 62.19
motif as immunogen represented the maximum breadth of
neutralization that could be induced against V3 loop
peptide target sequences. This limitation could be due to
inability of peptides to mirror the higher ordered structure
of native V3 in the Env oligomer, to inaccessibility of the
V3 loop on the surface of ¨60–70% of HIV-1 field
isolates, or to limited impact of bound V3-specific
antibodies on neutralization.
A recent analysis of the breadth of neutralization of the
most broadly reactive of the human V3 Mab, 447-52D, in the
single round pseudotype virion assay, found that the breadth
of 447-52D neutralization was similar to that of anti-62.19 V3
polyclonal sera, in that only a subset of subtype B was
neutralized (IC50, 45%) with few HIV-1 isolates neutralized
outside of subtype B (IC50, 5%) (Binley et al., 2004). This
experience with mab 447-52D suggests that neutralization
resistance to V3 antibodies is not solely due to limitations of
immunogenicity of V3 peptide immunogens, but rather more
likely relates to the physical inaccessibility of the V3 loop on
many HIV-1 primary isolates (Bou-Habib et al., 1994;
Schonning et al., 1996), and/or the lack of sensitivity of
many primary isolates to bound anti-V3 antibodies (Gorny et
al., 2004). This is further substantiated by the observation that
several of the difficult to neutralize isolates share V3 loop tip
sequences with the best V3 peptide immunogens. Moreover,
we have constructed C4–V3 peptides reflective of the V3
loop of HIV-1 6101, and this homologous peptide did not
induce antibodies that neutralize HIV-1 6101 (Haynes, B.F.,
Liao, H-X, and Montefiori, D.M., unpublished observations).
These data further substantiate the observations that a subset
of subtype B primary isolates are not susceptible to anti-V3
neutralization, regardless of the peptide immunogen design,
although it is possible that a modified design might improve
the conformation of the V3 peptides immunogen (Fontenot et
al., 1995). The current study was built on our previous
finding that C4–V3 peptides without coupling with a carrier
to stabilize structure are potent inducers of neutralizing
antibodies to T cell line adapted-HIV-1, but less so for
primary isolates (Liao et al., 2000). ELISA results using 447-
52D and 39F suggest structure in some peptides and not in
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of 29 peptides under the current study conditions. We have
previously shown that synthesizing the C4 N-terminal to the
V3 itself confers measurable structure to the V3 portion of the
peptides (Vu et al., 1999). Although coupling V3 peptides
with a carrier might stabilize structure as well to increase
immunogenicity, our attempts to couple some of our best
C4–V3 peptides (62.19 and 11.85) resulted in a loss of their
ability to induce neutralizing antibodies (Liao, H-X, Haynes,
BF. et al. unpublished observations).
Montefiori has previously shown that subtype C V3
peptides can absorb the neutralizing activity in sera from
patients infected with subtype C HIV-1 strains (Bures et al.,
2002). However, human anti-V3 mabs generally do not
neutralize subtype C primary isolates. For example, human
Mab 447 and a panel of other human anti-V3 mabs that
neutralize subtype B isolates did not neutralize subtype C
isolates (Binley et al., 2004; Gorny et al., 2002). In this study,
even the restricted but consistent neutralization induced by
subtype B V3 peptides for subtype B HIV-1 primary isolates
could not be duplicated for subtype C isolates by immune anti-
subtype B V3 sera.
Finally, regarding subtype B primary isolate neutralization,
the breadth of reactivity induced by peptide 62.19 for HIV-1
primary isolates is a significant improvement over previous
V3-based immunogens designs based on TCLA amino acid
sequences that induced no neutralizing activity against HIV-1
primary isolates (Vu et al., 1999) (Xia, S-M, Liao, H-X and
Haynes, B.F., unpublished observations). That several
rgp120s are recognized by the selected C4–V3 sera in the
present study, and a subset of subtype B primary isolates are
neutralized by anti-V3 sera, suggested that we indeed
succeeded in widening the breadth of neutralization obtained
with anti-V3 sera. The structural basis for why the 62.19
peptide may be advantageous is not known, but it is of
interest that the 62.19 peptide has an unusual negatively
charged amino acid, glutamic acid, in amino acid 328 that is
positioned to interact with arginine in position 311 on the
opposite side of the V3 hairpin, thereby possibly stabilizing
conformational determinant(s) of the V3 loop in the peptide
(Sharon et al., 2003).
In summary, the data from our study suggest that the
neutralizing breadth obtained with these selected V3 immuno-
gens is limited, and approximates the maximum breadth that
can be obtained for subtype B primary isolates with V3 peptide
immunogens alone. It will be important to determine if novel
formulations of V3 immunogens can increase the titer of
induced neutralizing antibodies such that breadth of neutrali-
zation is increased. Similarly, it will also be important to
determine if other species of anti-gp120 antibodies exist that
either induce exposure of the V3 loops on HIV-1 primary
isolates, or make primary isolates with exposed V3 loops more
susceptible to anti-V3 antibody-mediated neutralization. If
strategies cannot be devised to enhance the effectiveness of
anti-V3 antibodies, then the likelihood is that HIV-1 gp120 V3
peptide immunogens used alone will have limited utility as
HIV-1 vaccine candidates, although anti-V3 antibodies mayhave some utility as one component of a polyclonal vaccine-
stimulated immune response.
Methods
Peptide design, synthesis, and purification
Peptides were synthesized by SynPep, Inc. (Dublin, CA)
using F-MOC chemistry, purified by HPLC and the relative
molecular mass confirmed by mass spectrometry. The general
peptide design incorporated the gp120 fourth constant (C4)
region N-terminal to 22 to 24 aa of the V3 loop (Bartlett et al.,
1998; Haynes et al., 1995; Palker et al., 1988; Ping et al.,
1999). The C4 sequence KQIINMWQVVGKAMYA was
identical in all C4–V3 peptides.
A short antigenic region encompassing the beta turn at the
tip of the V3 loop was selected as a region likely to span
epitopes within the V3 loop; see the antibody section of the
HIV immunology database (www.hin.lanl.gov) (Korber et al.,
2001) for a full list of antibodies that bind to this region. All
subtype B sequences that spanned this region were extracted
from the 2001 HIV sequence database, and the data set was
reduced so that identical forms were included only once in a
final data set, retaining the number of times each form was
observed. A pairwise distance matrix was calculated for all
pairs of peptides, using an amino acid substitution matrix
developed to give substitutions that were well tolerated in
conserved protein structural elements a high score, and those
that were not, a low score (Henikoff and Henikoff, 1993). The
subtype B V3 sequences were organized into clusters of like-
sequences by using maximum-linkage clustering based on the
pairwise distance matrix (Korber et al., 1994). Clustering
peptide sequences according to amino acid conservation
enabled visualization of relationships between protein
sequences in a dendrogram. The dendrogram was divided
into clusters of related sequences at a level that would yield 30
clusters, as we felt it would be experimentally feasible to
sample and test the spectrum of antigenic diversity of subtype
B V3s with up to 30 peptides. Based on the clustering
patterns, alignments were generated, and we selected a V3
variant that was most representative of each cluster. We
excluded rare, highly divergent sequences, and favored
sequences found in many different individuals. This method
grouped most of the unique V3 sequences within one or two
amino acids from at least one of the peptides in the original
set. This strategy was an attempt to define a manageable set
that would cover the breadth of naturally occurring V3 loop
sequences.
Immunization regimens
Guinea pigs were immunized five times at 3-week intervals
with 250 Ag of peptide and bled 10 days after each
immunization. Adjuvants used were CFA/IFA subcutaneously
(S.Q.) (Sigma, St. Louis, MO) or RC529 intramuscularly (I.M.)
(Corixa, Seattle, WA) + mutant cholera toxin (mCT) (Wyeth,
Lederle Vaccines and Pediatrics, Pearl River, NY).
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Human anti-V3 mab 39F was obtained from James
Robinson, Tulane University, New Orleans, LA. Mab 447-
52D was obtained from the AIDS Research and Reference
Reagent Program, NIAID, donated by Susan Zolla-Pazner
(Gorny et al., 2004; Sharon et al., 2003). Recombinant HIV-1
Env Proteins, JRFL and BaL were obtained from QBI, Inc.,
Rockville, MD and the AIDS Research and Reference Reagent
Program, NIAID, NIH. HIV-1 Subtype C 97ZA012 env gene
was a gift of Gary Nabel, Vaccine Research Center, NIH. The
group M consensus envelope gp140 gene, CON6, was the gift
of Beatrice Hahn, University of Alabama at Birmingham, AL,
and Feng Gao, Duke University, and recombinant gp120 VBD-
2 (HIV-189.6) and VPE-50 (HIV-1IIIB) were the gifts of Pat Earl
and Bernard Moss, NIAID, Bethesda, MD. Soluble Env
proteins were produced from recombinant (r) vaccinia virus
(VV) by the methods of Moss and Earl (1998) and Gao et al.
(2005).
Neutralization assays
HIV-1 neutralization titers were measured either using a
multiple round infection assay in MT-2 cells as described (Bures
et al., 2002; Montefiori et al., 1998), a luciferase reporter gene-
based multiple-round HIV-1 inhibition assay (Liao et al., 2004),
or a single round pseudotype virion neutralization assay
(ViroLogic, Inc., South San Francisco, CA) (Richman et al.,
2003). In the luciferase reporter gene-based assay, neutralizing
antibodies were measured as a function of a reduction in
luciferase activity in 5.25.EGFP.Luc.M7 cells kindly provided
by Nathaniel R. Landau, Salk Institute, La Jolla, CA (Liao et al.,
2004). Five hundred tissue culture infectious dose 50 (TCID50)
of cell-free virus were incubated with indicated serum dilutions
in 150 Al (1 h, at 37 -C) in triplicate in 96-well flat-bottom
culture plates. The 5.25.EGFP.Luc.M7 cells were suspended at
a density of 5  105/ml in media containing DEAE dextran
(10 Ag/ml). Cells (100 Al) were added and cultured until 10% of
cells in control wells (no test serum sample) were positive for
GFP expression by fluorescence microscopy. At this time, 100
Al of cell suspension was transferred to a 96-well white solid
plate (Costar) for measurements of luminescence using Bright
Glo substrate solution as described by the supplier (Promega,
Madison, WI) on a Wallac 1420 Multilabel Counter (Perkin-
Elmer Life Sciences, Boston, MA). The MT-2 assay was
performed as described (Bures et al., 2002; Montefiori et al.,
1998). Neutralization titers in the MT-2 and luciferase reporter
gene-based assays are represented as 50% inhibitory concentra-
tions (IC50). The single round pseudotype virion assay was
performed as described (ViroLogic, Inc.) (Richman et al., 2003)
and neutralization titers are represented as IC50s. Neutralization
was considered positive if the IC50 was greater than 1:30
dilution of the serum sample. The initial screen of anti-V3
subtype B guinea pig sera was performed against the following
subtype B isolates: Dual A, Dual B, Dual C, Dual E, X4A, X4B,
X4C, X4D, SS1196, BaL, JRFL, SF162, TORNO, PAVO,
6101, 692, 5768, BG1168, and 515. Dual A, B, C, and D virusesare subtype B dual tropic HIV-1 primary isolate Env pseudo-
typed viruses. X4 A, B, C, and D are CXR4-utilizing HIV-1
primary isolate Env pseudotyped viruses. Since in this study, we
are determining ways to induce the maximum breadth of anti-
HIV neutralizing antibody responses, V3 immunogens were
identified as ‘‘best’’ by the number of HIV-1 isolates that were
neutralized.
Comparison of the Luc M7 and the single round pseudo-
virus neutralization assays demonstrated that neutralization
titers obtained in each assay were comparable (D. Montefiori et
al., unpublished observations).
ELISA assays
Reactivity of V3 Mab 39F and 447F with HIV-1 V3
peptides was determined in ELISA as described (Liao et al.,
2000).
Blue native gel analysis
Recombinant HIV-1 Bal gp120 (containing the V3 sequence
TRPNNNTRKSIHIGPGRAFYTTGEIIGDIRIQ) was from the
NIAID AIDS Reagent repository. HIV-1 89.6gp120 (contain-
ing the V3 sequence TRPNNNTRRRLSIGPGRAFYARR-
NIIGDIRQA), and cleavage site-deleted HIV-1 JRFL
gp140CF (containing the V3 sequence TRPNNNTRKSIHIGP-
GRAFYTTGEIIGDIRQA), 97ZA012 gp140CF ((containing
the V3 sequence TRPNNNTRKSMRIGPGQTFYATGDIIG-
DIRQA), and CON6 gp140CF (containing the V3 sequence
TRPNNNTRKSIHIGPGQAFYATGEIIGDIRQA) proteins
were produced in recombinant vaccinia viruses (rVVs) as
described previously (Gao et al., 2005). Reactivity of guinea
pig sera with HIV-1 gp120 or cleavage defective gp140
proteins was determined in blue native gel analysis as
described (Gao et al., 2005).
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